Social network
Our responsibility

Access to vaccines index: Sanofi’s strong performance

March 06, 2017

Children portrait

For the first time, the Access To Medicine Foundation launched its “Access To Vaccines Index” (ATV Index), which maps how 8 pharmaceutical companies – including Sanofi – are responding to global calls to increase immunisation coverage.


Vaccines are one of the most powerful and cost effective health interventions available. Yet, preventable diseases still cost millions of lives each year. Vaccine companies such as Sanofi are a key link in the chain to each successful vaccination.

Sanofi is among the four companies which account for 80% of global vaccine revenues. Sanofi’s vaccine portfolio size, revenue, volume of doses sold, and geographic scope are among the largest of companies in scope.

The ATV Index especially points out Sanofi’s world’s first dengue vaccine, Dengvaxia®, and its large R&D pipeline. Sanofi’s performance is strong in all areas of Manufacturing & Supply. In Pricing & Registration, Sanofi makes a general commitment to ensuring the prices of its vaccines are sustainable and equitable.

Regarding the portfolio, Sanofi currently has 38 vaccines on the market for 18 diseases in scope, which constitutes one of the largest portfolios of the companies measured by the ATV Index. Among these vaccines, many are recommended by the World Health Organization (WHO) for routine immunisation (e.g. for diphtheria, hepatitis B, Hib, pertussis, polio and tetanus).